Sign in Subscribe
Pharmaceutical industry

Post Menopausal Osteoporosis Pipeline Review: Identifying Key Players and Therapeutic Options

Strategic Insights

— 1 min read

Post menopausal osteoporosis is a condition characterized by the decline in bone density and increased risk of fractures after menopause. The pipeline for post menopausal osteoporosis has an extensive range of therapeutic options, with several companies actively developing treatments to address this condition. The report "Post Menopausal Osteoporosis - Pipeline Review, H1 2015" by RnRMarketResearch provides an in-depth analysis of the therapeutic development for post menopausal osteoporosis, including comparative analysis, therapeutics assessment, and updates on key players and their respective pipeline products.

The report highlights the key players in the post menopausal osteoporosis pipeline, including Amgen Inc., Chronos Therapeutics Limited, Eli Lilly and Company, Hanmi Pharmaceuticals, Co. Ltd., Merck & Co., Inc., Oncobiologics, Inc., Paras Biopharmaceuticals Finland Oy, Pfizer Inc., Radius Health, Inc., and Unigene Laboratories, Inc. These companies have developed various therapeutic options, including (aceclofenac + eperisone), abaloparatide, bazedoxifene acetate, blosozumab, calcitonin, denosumab, denosumab biosimilar, odanacatib, RDC-5, romosozumab, and teriparatide biosimilar, to address post menopausal osteoporosis.

Key Takeaways:

  • The pipeline for post menopausal osteoporosis is extensive, with 26 products under development by 11 companies.
  • The report provides a comprehensive analysis of the therapeutic development for post menopausal osteoporosis, including comparative analysis, therapeutics assessment, and updates on key players and their respective pipeline products.
  • Several companies have developed therapeutic options that target cell signaling pathways, such as the Wnt/β-catenin and TGF-β pathways.
  • The report highlights the importance of post menopausal osteoporosis pipeline development, with several companies actively pursuing late-stage development and regulatory approval for their respective products.
  • Amgen Inc. and Eli Lilly and Company lead the post menopausal osteoporosis pipeline, with the largest number of products under development.

Statistics:

  • 26 products are under development for post menopausal osteoporosis in the pipeline.
  • 11 companies have pipeline products for post menopausal osteoporosis.
  • The post menopausal osteoporosis pipeline includes 14 projects in the late-stage development.
  • 4 out of the top 5 companies have pipeline products in late-stage development.
  • Abaloparatide, developed by Radius Health, Inc., is a leading product in the pipeline.

Sources:

  • RnRMarketResearch.com
  • "Post Menopausal Osteoporosis - Pipeline Review, H1 2015"
  • Amgen Inc.
  • Chronos Therapeutics Limited
  • Eli Lilly and Company
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Merck & Co., Inc.
  • Oncobiologics, Inc.
  • Paras Biopharmaceuticals Finland Oy
  • Pfizer Inc.
  • Radius Health, Inc.
  • Unigene Laboratories, Inc.

Read more